Abstract
Background: Tuberculosis (TB) remains one of the most significant infectious diseases globally, with inflammatory markers serving as potential indicators of disease severity and treatment response. Aim and Objectives: To compare the levels of hs-CRP, ESR, WBC, LDH, and procalcitonin between patients with drug-sensitive pulmonary tuberculosis (DS-PTB) and rifampicin-resistant pulmonary tuberculosis (RR-PTB) before and after two months of anti-tubercular therapy (ATT) under NTEP guidelines. Materials and Methods: A prospective comparative study was conducted from March 2025 to September 2025 including 70 DS-PTB and 68 RR-PTB patients. Baseline and 2-month inflammatory markers were analyzed. Statistical tests included Shapiro-Wilk, Mann-Whitney U, independent t-test, paired t-test/Wilcoxon signed-rank test, Chi-square/Fisher’s exact test, and Spearman correlation. A p-value <0.05 was considered statistically significant. Results: Baseline inflammatory markers were higher in the RR-PTB group compared to DS-PTB (p>0.05 for most). After two months of ATT, both groups showed a decline in hs-CRP, ESR, LDH, and procalcitonin, though not statistically significant (p>0.05). No significant correlation was observed between post-therapy inflammatory markers and treatment type. Conclusion: The study found no statistically significant improvement in inflammatory markers after two months of therapy in either arm, suggesting that short-term biochemical response may not directly correspond with microbiological improvement.
Introduction
Tuberculosis (TB) remains a global health crisis, with India bearing nearly a quarter of the world's cases. A major challenge for clinicians is monitoring patient response to Anti-Tubercular Therapy (ATT), especially in cases of drug resistance. While microbiological tests like sputum conversion are the gold standard, they are time-consuming. Researchers have looked to systemic inflammatory markers—such as high-sensitivity C-reactive protein (hs-CRP) and Erythrocyte Sedimentation Rate (ESR)—as potential "real-time" proxies for disease activity. This study evaluates whether these markers can serve as early indicators of therapeutic response during the intensive phase (first two months) of treatment under the National TB Elimination Programme (NTEP) guidelines.
Methods
The authors conducted a prospective observational study at a tertiary care hospital in Bhopal, India, involving 138 patients (70 with DS-PTB and 68 with RR-PTB). The study measured five key inflammatory parameters at baseline and after two months of standard ATT: hs-CRP, ESR, White Blood Cell (WBC) count, Lactate Dehydrogenase (LDH), and Procalcitonin. Diagnosis was confirmed using GeneXpert MTB/RIF and line probe assays. Statistical analysis utilized the Shapiro-Wilk test for normality, followed by t-tests or Mann-Whitney U tests for comparisons, and Spearman correlation to find relationships between markers.
Results
Baseline Inflammation and Resistance
Patients with rifampicin-resistant TB (RR-PTB) entered the study with higher baseline levels of hs-CRP, ESR, and LDH compared to the drug-sensitive group, suggesting that drug-resistant strains may provoke a more intense systemic inflammatory response. Notably, 81% of RR-PTB patients had a prior history of TB treatment, compared to only 25% in the drug-sensitive group.
The "Biochemical Lag"
Even though patients generally show clinical improvement (weight gain, reduced cough) within two months, their blood chemistry does not always reflect this recovery immediately. The study found that while markers trended downward, the drop was not statistically significant ($p > 0.05$).
As shown in Figure 1, median ESR fell from 56 to 38 mm/hr in the DS-PTB group and 62 to 47 mm/hr in the RR-PTB group ($p=0.09$). Similarly, hs-CRP levels showed a downward trend that failed to reach statistical significance ($p=0.08$).
In the DS-PTB group, hs-CRP levels dropped from $18.6 \pm 4.2$ mg/L to $10.9 \pm 3.7$ mg/L. In the RR-PTB group, they dropped from $20.2 \pm 5.6$ mg/L to $13.8 \pm 4.9$ mg/L. The scatter plots reveal high inter-individual variability; while many patients saw reductions (points below the $y=x$ reference line), others remained stagnant despite high treatment adherence (>90%).
Discussion and Conclusion
The lack of a significant difference in the rate of decline between the two groups suggests that host immune activation pathways are similar, regardless of whether the TB strain is drug-sensitive or resistant. However, the "biochemical lag" observed suggests that standard inflammatory markers may not be reliable short-term predictors of treatment success during the intensive phase.
Limitations and Future Work
The authors acknowledge that the two-month timeframe may be too short to capture significant biochemical shifts. Additionally, markers like CRP and LDH are sensitive but non-specific, potentially influenced by co-existing conditions like malnutrition. Future research should focus on longer-term follow-up and the integration of molecular markers with radiological data to determine if biochemical monitoring can eventually augment microbiological assessment.
Summary updated